Key Takeaways
Amphastar Pharmaceuticals (AMPH) has experienced a tumultuous period, with its stock price plummeting by 36% year-to-date, now trading at $17.20 as of May 18, 2026. This sharp decline, which saw shares fall from $26.78 at the start of the year, reflects a series of disappointing financial results and increasing market skepticism. The most recent blow came after the Q1 2026 earnings report on May 7, 2026, where the company missed analyst expectations on both revenue and earnings, leading to a 19.1% single-day drop in the stock. This follows a similar pattern from Q4 2025, where revenue and EPS also fell short, causing an 11.7% immediate dip.
The core issue appears to be a significant contraction in profitability, with the adjusted operating margin falling to 13.4% in Q1 2026, a substantial 17.1 percentage point decrease year-over-year. This margin compression is largely attributed to increased competition and pricing pressure on legacy products like glucagon injection and epinephrine multi-dose vials. While the company's proprietary product, BAQSIMI, continues to show strong growth, its momentum has not been enough to offset the broader declines and margin erosion. The market capitalization has shrunk to $758.4 million, placing AMPH firmly in small-cap territory and highlighting the severity of investor concerns.
The company's long-term growth narrative, which once boasted a 38.4% compounded annual growth rate in EPS over the last five years, is now being questioned. Despite a five-year average operating margin of 24.5%, recent performance shows a 7.7 percentage point decrease on a two-year basis. This inconsistency in profitability, coupled with revenue growth deceleration (annualized revenue growth of 5.4% over the last two years, below its five-year trend of 15.5%), suggests that Amphastar is struggling to adapt to a more competitive pharmaceutical landscape. Investors are now grappling with whether the current valuation reflects a potential buying opportunity or if further downside is imminent given the persistent operational challenges.
Amphastar Pharmaceuticals' Q1 2026 results, reported on May 7, 2026, were a significant miss across key metrics, triggering a substantial sell-off in the stock. The company reported adjusted earnings per share (EPS) of just $0.42, falling well short of the Zacks Consensus Estimate of $0.70 by 40.5%. This marked a sharp 43% drop from the $0.74 EPS reported in the same period last year. Revenue also disappointed, coming in at $171.2 million, which was flat year-over-year and missed analyst expectations of $173.46 million by 1.1%. This dual miss on both top and bottom lines signaled deeper operational issues than initially perceived by the market.
The primary driver of this underperformance was severe margin contraction. The adjusted operating income plummeted to $22.9 million, a staggering 47.7% below Wall Street's expectations. Consequently, the adjusted operating margin fell dramatically to 13.4%, representing a 17.1 percentage point decline from the prior year's quarter. This contraction indicates that Amphastar's expenses increased significantly relative to its revenue, eroding profitability. CFO William J. Peters acknowledged that duplicated rebates related to 340B pharmacies were under third-party review, a factor that likely contributed to the reduced net income.
Management also highlighted increased competition in legacy products, specifically glucagon injection and epinephrine multi-dose vials, as a major headwind. Sales of these older products dropped sharply, with prescribers shifting towards newer, ready-to-use alternatives like BAQSIMI. While BAQSIMI, the nasal glucagon product acquired from Eli Lilly, delivered 21% year-over-year revenue growth, this strong performance was insufficient to fully offset the declines in other segments. The company's R&D expenses also rose 14% year-over-year, driven by higher material and clinical trial costs, further impacting the bottom line in a quarter where top-line growth was absent.
Despite the recent financial setbacks, Amphastar Pharmaceuticals is pinning its hopes on new product launches and the continued momentum of BAQSIMI to drive future growth. A key development is the FDA approval and April 2026 launch of ipratropium bromide inhalation (AMP-007), which management expects to be a major growth driver for 2026. This product currently faces no generic competition, offering a potential high-margin revenue stream. CEO Dan Dischner also emphasized the strong brand recognition of Primatene MIST, which has 60 years of market presence, and the regulatory challenges generics would face entering its over-the-counter market.
BAQSIMI, the company's nasal glucagon product, remains a significant asset, having recorded its highest quarterly sales since its acquisition and delivering 21% year-over-year revenue growth in Q2 2025. Management expects BAQSIMI to continue as a top performer, projecting high single-digit unit growth and a 3% price increase in the U.S. The co-promotion agreement with MannKind is also anticipated to enhance BAQSIMI's commercial reach in the second half of 2026. These proprietary products are crucial for shifting Amphastar's revenue mix towards higher-margin therapies and away from commoditized generics.
Looking further ahead, Amphastar's pipeline includes several promising candidates. The insulin aspart biosimilar (AMP-004) and a GLP-1 ANDA remain on track for commercial launch in 2027, with no changes to their regulatory milestones. The company also signed an exclusive in-licensing agreement with Nanjing Anji Biotechnology, adding three novel peptide candidates targeting oncology and ophthalmology, which could diversify its therapeutic portfolio. Management aims for proprietary products to comprise 50% of its pipeline by 2026 and expects double-digit growth in 2026, with BAQSIMI as the number one growth product. These pipeline advancements and the strategic focus on proprietary assets are critical for reversing the recent negative trends.
Amphastar Pharmaceuticals faces several significant risks that could impede its recovery and future growth, leading to increased caution among analysts. The most pressing concern is the intensifying pricing pressure and competition in its legacy product lines, particularly glucagon and epinephrine. Management has repeatedly warned of further erosion in these segments as additional competitors enter the market and prescribers shift to newer, ready-to-use alternatives. This competitive landscape directly impacts revenue and gross margins, as evidenced by the sharp 17.1 percentage point drop in operating margin in Q1 2026.
Analyst sentiment has notably soured in recent months. On May 14, 2026, Wells Fargo downgraded AMPH to 'Equal-Weight' from 'Overweight' and drastically lowered its price target from $30 to $19. This followed a broader trend of price target reductions, with the consensus price target falling from $26.86 to $23.33 on May 15, 2026. Analysts from institutions like Needham & Company, Wells Fargo, Bank of America, and JPMorgan have consistently questioned management on flat revenue outlooks, glucagon erosion, and margin trends. The consensus EPS estimates for fiscal year 2026 have also deteriorated significantly, falling by 38% from $2.16 per share to $1.34 per share, with the net income forecast to shrink 13% next year.
Pipeline execution risk is another major concern. While new products like AMP-007 and AMP-015 are anticipated, regulatory delays and agency bandwidth constraints could push back launch timelines. For instance, the synthetic corticotropin (AMP-110) pipeline candidate has no regulatory alignment yet for accelerated approval, with Phase 1 entry targeted for 2027. Furthermore, the GLP-1 market is expected to be crowded, limiting the near-term revenue impact of AMP-018. These uncertainties, combined with the ongoing challenges in stabilizing margins and the company's underperformance relative to the broader U.S. pharmaceuticals industry (AMPH returned -31.95% over the past year vs. the industry's 34.5%), paint a cautious outlook for investors.
Following its substantial stock price decline, Amphastar Pharmaceuticals' valuation metrics warrant a closer look to determine if the market has overcorrected. The stock is currently trading at $17.20, significantly below its 52-week high of $31.26. Its trailing P/E ratio stands at 11.45 as of May 8, 2026, which appears relatively low compared to the broader pharmaceutical sector. The price-to-sales (TTM) ratio is 1.25, and the price-to-book (MRQ) is 1.08, suggesting that the company is trading at a discount compared to its historical averages and potentially some peers.
However, the declining earnings outlook casts a shadow on these seemingly attractive multiples. The consensus EPS estimate for fiscal year 2026 has been slashed to $1.34 per share from $2.16, implying a forward P/E that would be higher than the trailing figure if current estimates hold. The average analyst price target has also decreased to $23.33, which still suggests a potential upside of approximately 35.6% from the current $17.20 share price. This indicates that while analysts have become more conservative, they still see some value in the stock at these depressed levels.
The market capitalization of $758.4 million reflects a company facing significant operational challenges, yet with a pipeline that holds future promise. The company's recent $29.5 million share repurchase in Q1 2026 signals management's belief in the intrinsic value of the stock, potentially viewing the current price as undervalued. However, investors must weigh the potential for pipeline success and BAQSIMI's continued growth against the persistent margin pressures, intense competition, and the overall negative trend in profitability. The stock's current position near its 52-week low of $16.64 suggests that much of the negative news may already be priced in, but a clear catalyst for sustained recovery remains elusive.
Amphastar Pharmaceuticals is currently navigating a challenging period marked by significant earnings misses and margin compression, leading to a substantial stock price decline. While new product launches and BAQSIMI's performance offer a glimmer of hope, intense competition and analyst downgrades underscore the uphill battle ahead. Investors should monitor the progress of pipeline approvals, the impact of U.S. manufacturing expansion, and management's ability to stabilize margins to assess the company's long-term viability.
Want deeper research on any stock? Try Kavout Pro for AI-powered analysis, smart signals, and more. Already a member? Add credits to run more research.
